EyePoint Pharmaceuticals, Inc.

EYPT

NASDAQ

Healthcare

Biotechnology

Watertown, MA, US165 employeeseyepointpharma.com

$13.41

+0.39(3.00%)

Mkt Cap $1.1B

$4.13

$18.85

52-Week Range

At a Glance

AI-generated

EyePoint Pharmaceuticals, Inc.

Revenue breakdown: License And Collaboration Agreement (37%), Product Rights Agreement (34.6%), Royalty (10.1%).

8-K

EyePoint Pharmaceuticals, Inc. announced Q4 and full-year 2025 financial results with total net revenue of $0.6 million and $31.4 million, respectively, and net losses of $67.6 million and $232.0 million. The company reported $306 million in cash providing runway into Q4 2027, Phase 3 trial progress for DURAVYU in wet AMD and DME, and appointed Michael Campbell as Chief Commercial Officer.

$1.1B

Market Cap

$32M

Revenue

-$233M

Net Income

Employees165

Fundamentals

How The Business Makes Money

Revenue by Segment

License And Collaboration Agreement37%($57M)

Product Rights Agreement34.6%($53M)

Royalty10.1%($16M)

Royalty Purchase Agreement9%($14M)

Product6.2%($9M)

YUTIQ Product3.1%($5M)

Revenue by Geography

US96.5%($72M)

CN3.2%($2M)

GB0.3%($200.0K)

Activity

What Changed Recently

Financial Results

Mar 3, 2026

Results of Operations and Financial Condition. On March 4, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its financial results for the

Financial Results

Jan 6, 2026

of this current report on Form 8-K, including Exhibit 99.1, is deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and

Other Event

Mar 1, 2026

Other Events. On March 2, 2026, EyePoint, Inc. issued a press release announcing the first patients dosed in both COMO and CAPRI, the Company's Phase 3 clinical

Peer Companies

Company	Price	Change	Market Cap	P/E
TNGXTango Therapeutics, Inc.	$21.66	+2.07%	$2.5B	-21.7
KODKodiak Sciences Inc.	$40.55	-5.28%	$2.1B	-5.4
NRIXNurix Therapeutics, Inc.	$15.51	+0.16%	$1.3B	-5.3
BCAXBicara Therapeutics Inc. ...	$21.48	+4.78%	$1.2B	-8.3
SVRASavara Inc.	$5.57	-0.27%	$1.1B	-9.5
SEPNSepterna, Inc.	$25.20	+3.43%	$1.1B	-21.5
KURAKura Oncology, Inc.	$8.62	+3.36%	$761M	-2.6
PRMEPrime Medicine, Inc.	$3.31	-2.36%	$598M	-2.6

Analyst View

Company Profile

CIK0001314102

ISINUS30233G2093

CUSIP30233G209

Phone617 926 5000

Address480 Pleasant Street, Watertown, MA, 02472, US

SEC EDGAR